Lokon Pharma and Affibody initiate a collaboration to develop novel cancer therapeutics

Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB (“Affibody”) to combine oncolytic viruses with Affibody® molecules.

“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says Dr. Angelica Loskog, the CEO of Lokon Pharma. She adds, “Affibody’s proprietary antibody mimetics are small proteins with high affinity to desired targets and well suited to combine with our LOAd platform viruses. We are excited to initiate this new collaboration aiming to develop a novel treatment regime for selected cancer indications”.

“We are enthusiastic about investigating this potential extension of our Affibody® technology platform by collaborating with leading researchers in the oncolytic virus field”, says Prof. Fredrik Frejd, CSO of Affibody. “The small size of and potential for high affinity makes Affibody® molecules highly interesting tools for a novel treatment regime with adenovirus platforms”.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>